233 related articles for article (PubMed ID: 33690080)
1. Deletion of serine/threonine-protein kinase pknL from Mycobacterium tuberculosis reduces the efficacy of isoniazid and ethambutol.
Naz S; Singh Y; Nandicoori VK
Tuberculosis (Edinb); 2021 May; 128():102066. PubMed ID: 33690080
[TBL] [Abstract][Full Text] [Related]
2. Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
Lounis N; Maslo C; Truffot-Pernot C; Grosset J; Boelaert RJ
Int J Tuberc Lung Dis; 2003 Jun; 7(6):575-9. PubMed ID: 12797701
[TBL] [Abstract][Full Text] [Related]
3. Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
Shi R; Zhang J; Otomo K; Zhang G; Sugawara I
Antimicrob Agents Chemother; 2007 Dec; 51(12):4515-7. PubMed ID: 17846128
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the Mycobacterium tuberculosis pknH gene confers a higher bacillary load during the chronic phase of infection in BALB/c mice.
Papavinasasundaram KG; Chan B; Chung JH; Colston MJ; Davis EO; Av-Gay Y
J Bacteriol; 2005 Aug; 187(16):5751-60. PubMed ID: 16077122
[TBL] [Abstract][Full Text] [Related]
5. The "in vitro" activity of rifampicin compared with ethambutol, capreomycin and isoniazid.
Steinbrück PW
Acta Tuberc Pneumol Belg; 1969; 60(3):413-6. PubMed ID: 4984421
[No Abstract] [Full Text] [Related]
6. Simultaneous ethambutol & isoniazid resistance in clinical isolates of Mycobacterium tuberculosis.
Gupta P; Jadaun GP; Das R; Gupta UD; Srivastava K; Chauhan A; Sharma VD; Chauhan DS; Katoch VM
Indian J Med Res; 2006 Feb; 123(2):125-30. PubMed ID: 16575110
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of ciprofloxacin in combination with standard antituberculous drugs against mycobacterium tuberculosis.
Uttley AH; Collins CH
Tubercle; 1988 Sep; 69(3):193-5. PubMed ID: 3151140
[TBL] [Abstract][Full Text] [Related]
8. A Serine/threonine kinase PknL, is involved in the adaptive response of Mycobacterium tuberculosis.
Refaya AK; Sharma D; Kumar V; Bisht D; Narayanan S
Microbiol Res; 2016 Sep; 190():1-11. PubMed ID: 27393993
[TBL] [Abstract][Full Text] [Related]
9. PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Gupta A; Pal SK; Pandey D; Fakir NA; Rathod S; Sinha D; SivaKumar S; Sinha P; Periera M; Balgam S; Sekar G; UmaDevi KR; Anupurba S; Nema V
Ann Clin Microbiol Antimicrob; 2017 Aug; 16(1):56. PubMed ID: 28821299
[TBL] [Abstract][Full Text] [Related]
10. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol.
Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D
Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203
[TBL] [Abstract][Full Text] [Related]
11. Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia.
Tessema B; Beer J; Emmrich F; Sack U; Rodloff AC
BMC Infect Dis; 2012 Feb; 12():37. PubMed ID: 22325147
[TBL] [Abstract][Full Text] [Related]
12. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
[TBL] [Abstract][Full Text] [Related]
13. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
14. [Testing Mycobacterium tuberculosis for drug sensitivity using different methods].
Skriagina EM; Zalutskaia OM; Roth A; Mauch H; Nikolenko EN
Probl Tuberk; 2001; (5):43-5. PubMed ID: 11588962
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
Schön T; Juréen P; Giske CG; Chryssanthou E; Sturegård E; Werngren J; Kahlmeter G; Hoffner SE; Angeby KA
J Antimicrob Chemother; 2009 Oct; 64(4):786-93. PubMed ID: 19633001
[TBL] [Abstract][Full Text] [Related]
16. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
[TBL] [Abstract][Full Text] [Related]
17. Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
Genestet C; Hodille E; Berland JL; Ginevra C; Bryant JE; Ader F; Lina G; Dumitrescu O;
Int J Antimicrob Agents; 2020 Apr; 55(4):105912. PubMed ID: 31991222
[TBL] [Abstract][Full Text] [Related]
18.
Swaminath S; Paul A; Pradhan A; Sebastian J; Nair RR; Ajitkumar P
Microbiology (Reading); 2020 Feb; 166(2):180-198. PubMed ID: 31746727
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.
Eltringham IJ; Wilson SM; Drobniewski FA
J Clin Microbiol; 1999 Nov; 37(11):3528-32. PubMed ID: 10523547
[TBL] [Abstract][Full Text] [Related]
20. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin.
Safi H; Sayers B; Hazbón MH; Alland D
Antimicrob Agents Chemother; 2008 Jun; 52(6):2027-34. PubMed ID: 18378710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
